Pfizer Total Current Assets 2010-2024 | PFE
Pfizer total current assets from 2010 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
- Pfizer total current assets for the quarter ending September 30, 2024 were $37.825B, a 48.43% decline year-over-year.
- Pfizer total current assets for 2023 were $43.333B, a 15.46% decline from 2022.
- Pfizer total current assets for 2022 were $51.259B, a 14.13% decline from 2021.
- Pfizer total current assets for 2021 were $59.693B, a 70.23% increase from 2020.
Pfizer Annual Total Current Assets
(Millions of US $) |
| 2023 |
$43,333 |
| 2022 |
$51,259 |
| 2021 |
$59,693 |
| 2020 |
$35,067 |
| 2019 |
$32,803 |
| 2018 |
$49,926 |
| 2017 |
$41,141 |
| 2016 |
$38,949 |
| 2015 |
$43,804 |
| 2014 |
$55,595 |
| 2013 |
$56,244 |
| 2012 |
$64,831 |
| 2011 |
$60,817 |
| 2010 |
$61,013 |
| 2009 |
$61,670 |
Pfizer Quarterly Total Current Assets
(Millions of US $) |
| 2024-06-30 |
$37,825 |
| 2024-03-31 |
$42,415 |
| 2023-12-31 |
$43,333 |
| 2023-09-30 |
$74,012 |
| 2023-06-30 |
$73,347 |
| 2023-03-31 |
$50,078 |
| 2022-12-31 |
$51,259 |
| 2022-09-30 |
$70,403 |
| 2022-06-30 |
$67,466 |
| 2022-03-31 |
$54,420 |
| 2021-12-31 |
$59,693 |
| 2021-09-30 |
$57,900 |
| 2021-06-30 |
$48,814 |
| 2021-03-31 |
$39,533 |
| 2020-12-31 |
$35,067 |
| 2020-09-30 |
$47,739 |
| 2020-06-30 |
$46,424 |
| 2020-03-31 |
$34,738 |
| 2019-12-31 |
$32,803 |
| 2019-09-30 |
$33,459 |
| 2019-06-30 |
$47,073 |
| 2019-03-31 |
$45,290 |
| 2018-12-31 |
$49,926 |
| 2018-09-30 |
$41,583 |
| 2018-06-30 |
$37,303 |
| 2018-03-31 |
$34,835 |
| 2017-12-31 |
$41,141 |
| 2017-09-30 |
$40,291 |
| 2017-06-30 |
$36,385 |
| 2017-03-31 |
$35,878 |
| 2016-12-31 |
$38,949 |
| 2016-09-30 |
$38,501 |
| 2016-06-30 |
$43,845 |
| 2016-03-31 |
$41,298 |
| 2015-12-31 |
$43,804 |
| 2015-09-30 |
$45,001 |
| 2015-06-30 |
$51,715 |
| 2015-03-31 |
$49,443 |
| 2014-12-31 |
$55,595 |
| 2014-09-30 |
$56,987 |
| 2014-06-30 |
$58,287 |
| 2014-03-31 |
$57,793 |
| 2013-12-31 |
$56,244 |
| 2013-09-30 |
$59,500 |
| 2013-06-30 |
$61,435 |
| 2013-03-31 |
$64,763 |
| 2012-12-31 |
$64,831 |
| 2012-09-30 |
$57,127 |
| 2012-06-30 |
$58,765 |
| 2012-03-31 |
$54,863 |
| 2011-12-31 |
$60,817 |
| 2011-09-30 |
$62,732 |
| 2011-06-30 |
$60,484 |
| 2011-03-31 |
$58,244 |
| 2010-12-31 |
$61,013 |
| 2010-09-30 |
$54,089 |
| 2010-06-30 |
$51,101 |
| 2010-03-31 |
$49,916 |
| 2009-12-31 |
$61,670 |
| 2009-09-30 |
$73,784 |
| 2009-06-30 |
$71,550 |
| 2009-03-31 |
$54,253 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$151.422B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
